Intech Biopharm Corporation (TPEX:6461)

Market Cap	3.54B
Revenue (ttm)	113.85M
Net Income (ttm)	-370.35M
Shares Out	162.92M
EPS (ttm)	-2.55
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	955,823
Average Volume	1,063,036
Open	22.95
Previous Close	22.95
Day's Range	21.50 - 22.95
52-Week Range	14.10 - 28.00
Beta	-0.15
RSI	62.16
Earnings Date	Mar 11, 2026

About Intech Biopharm

Intech Biopharm Corporation engages in developing and manufacturing generic drugs to treat respiratory diseases in Taiwan and internationally. It owns iLEF (inhaled low ethanol formulation), a metered dose inhaler platform for treating asthma and COPD; and dry powder inhaler, a product comprises of blisters and capsules. The company offers its products under the SYN006, SYN010, SYN007, Synflutide, Duasma, Synvent, and SYN011 names. Intech Biopharm Corporation was founded in 2010 and is headquartered in Taipei, Taiwan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 90
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6461

Financial Performance

In 2024, Intech Biopharm's revenue was 39.78 million, an increase of 53.90% compared to the previous year's 25.85 million. Losses were -368.21 million, 8.94% more than in 2023.